Home -> Law Blog Directory -> Patent Law Blogs -> IPBiz

Patent Law

: IPBiz

Geron blames air-bags for lack of progress?!?

By Lawrence B. Ebert, Esq.

IPBiz has posted on Geron many times, including some rather interesting patent stories. A post on TheStreet on August 19 concerning an FDA clinical hold on Geron tests included some rather interesting text.

First, one had a complaint about lack of achievement:

My beef with Geron is the company's chronic under-achievement, except when it comes to spending shareholders' money. One could say the same thing about Proposition 71 and CIRM.

Second, was an allusion to an excuse offered by Geron:

In this case, Geron promised to enroll the first paralyzed patients into its stem cell trial during the summer. That announcement was made in January. Yet August is rolling toward a hot and humid finish here in the Northeast, and the study is nowhere close to starting. Last month, the company told investors that car airbags were partly to blame for the delay. (Airbags protect drivers and passengers in accidents, making it hard to find traffic accident victims with paralysis severe enough to be eligible for the clinical trial, or so Geron CEO Tom Okarma said on his company's quarterly conference call.)

What can one say?

**Of the past, there is much of interest to patent attorneys in the interference between ACT and Geron.

From an IPBiz post in 2005:
Geron prevails in patent interference against ACT in stem cell area

Also: http://ipbiz.blogspot.com/2004/12/geron-obtains-another-stem-cell-patent.html

Full post as published by IPBiz on August 20, 2009 (boomark / email).